This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Champions Oncology (CSBR) Q3 Earnings: What's in Store?
by Zacks Equity Research
During Champions Oncology's (CSBR) third-quarter fiscal 2019 conference call, investor focus will be on the company's progress with its Ex Vivo platform and services.
What's in the Cards for Novavax (NVAX) This Earnings Season?
by Zacks Equity Research
Novavax (NVAX) is expected to provide updates on its lead vaccine candidate, Resvax when it reports fourth-quarter 2018 results.
Why Marijuana ETFs & Stocks Have More Room to Run
by Sanghamitra Saha
Marijuana stocks and ETFs are hot this year and can perform better in the coming days.
Cronos (CRON) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline progress when Cronos (CRON) reports fourth-quarter results.
Top Performing ETF Areas of February
by Sanghamitra Saha
Let's take look at the top ETF areas of February 2019.
Options Traders Expect Huge Moves in Tilray (TLRY) Stock
by Zacks Equity Research
Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.
Tilray, Inc. (TLRY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Tilray, Inc. (TLRY) closed at $79.07, marking a -0.16% move from the previous day.
Marijuana Stocks and ETFs: Risks and Rewards
by Neena Mishra
Pot stocks are soaring again. To learn more about risks and rewards of investing in marijuana stocks and ETFs, check out this Exploring ETFs video.
What Investors Need to Know About Investing in Marijuana Stocks
by Benjamin Rains
Let's look at what investors need to know about the marijuana industry and how to invest in the future of pot.
Tilray's Deal to Buy Hemp Food Maker Bolsters Marijuana ETF
by Sweta Killa
Tilray's deal to acquire the hemp food maker Manitoba Harvest has bolstered the outlook of the already high-flying marijuana ETF.
Tilray, Inc. (TLRY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed at $76.49 in the latest trading session, marking a -0.17% move from the prior day.
4 Reasons Why Marijuana Stocks & ETFs Could Be on a High in 2019
by Sanghamitra Saha
Marijuana stocks and related ETFs caught investors' attention last year, courtesy of its mysterious rally in mid-2018 on Canada's legalization of recreational marijuana in October. Let's take a look at whether the space will be able to maintain its rally in 2019.
Pot Stocks: Who Has the Best Earnings Chart?
by Tracey Ryniec
Pot stocks are entering the investing mainstream but do they have what it takes to compete against mature industries?
Tilray, Inc. (TLRY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed at $79.24 in the latest trading session, marking a -0.94% move from the prior day.
Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline progress and updates when Tilray (TLRY) reports fourth-quarter results.
Will Q4 Results Continue to Fuel Momentum in Marijuana ETF?
by Sweta Killa
Investors are keenly watching whether legalization is living up to the hype in the quarterly results of the cannabis stocks.
Buy the Dip in Marijuana Stocks & ETF?
by Sanghamitra Saha
Marijuana stocks and ETF slumped on Feb 6. Is this the time to buy?
Where to Find the Best Marijuana Stocks
by Tracey Ryniec
As the marijuana industry gets more complex, check out the Zacks Market Edge Podcast where host Tracey Ryniec
Pot Stocks are on a High: Play These Marijuana ETFs
by Sanghamitra Saha
As marijuana stocks soar into the new year, which ETFs should investors consider?
The Zacks Analyst Blog Highlights: Cronos, Altria, Canopy and Tilray
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cronos, Altria, Canopy and Tilray
Here's Why Cannabis Stocks (ACB, CRON) Are Gaining Today
by Ryan McQueeney
Shares of several notable cannabis stocks, including Aurora Cannabis (ACB) and Cronos Group (CRON), were up more than 10% through early afternoon trading hours Monday.
Tilray, Inc. (TLRY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Tilray, Inc. (TLRY) closed at $81.91 in the latest trading session, marking a +1.76% move from the prior day.
What Makes Marijuana ETF the Best Performer in January?
by Sanghamitra Saha
These are the factors that led marijuana ETF to see a strong start to 2019.
Tilray, Inc. (TLRY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Tilray, Inc. (TLRY) closed at $71.74, marking a -1.46% move from the previous day.
Earnings from Netflix & Big Banks, & This Week in Cannabis Deals
by Ryan McQueeney
Ryan McQueeney and Maddy Johnson discuss earnings results from Netflix and the big U.S. banks. The hosts also remember the legacy of Jack Bogle and chat about several new cannabis industry deals.